AX-2025-019336 · Epitalon · AMB lot AMB-2411-X6617

Section 1

Results

Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.93	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — aspartimide (−18 Da)	0.04	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.87	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	14.56	%	≤ 10.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.98	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	3.97	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	5.09	min	4.62 ± 0.20 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.95	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	78,000	—	≥ 20,000	PASS
Resolution to nearest impurity	vs aspartimide (−18 Da)	1.61	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 78,000, and skew follows the reported asymmetry factor of 0.95. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Epitalon — main peak	5.09	4,856,908	99.93	—
2	aspartimide (−18 Da)	5.21	1,944	0.04	-18.011
3	diketopiperazine (−18 Da)	5.25	1,458	0.03	-18.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence -0.02 pp vs batch median
Total impurities (% area)	0.10	0.07
Largest single impurity (% area)	not stated	0.04
Water (%)	4.4	5.87
Counter-ion (%)	8.2	14.56
Peptide content (%w/w)	86.8	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 30 d) → laboratory (courier, ambient, 7 d) → assay.
Assay date: 27 May 2025
Submitted to the index: 28 May 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 5

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

chain_custody28 May 2025

A retail vial at 99.93 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.

lot_traceability28 May 2025

Lot AMB-2411-X6617 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.

price_per_mg28 May 2025

A retail purchase carries a price, which makes cost per milligram of recovered peptide computable. That is the comparison a buyer actually needs and it exists only for this provenance class.

low_n28 May 2025

Strong provenance does not fix small n. One well-sourced record is still one record, and the batch page says how many others exist for AMB-2411-X6617.

tri_agonist28 May 2025

Reading the record the same way.

Section 7

Related records

Same batch — lot AMB-2411-X6617 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019331	AMB-2411-X6617	PeptideMeter	2025-Q2	99.89	6.06	94.5	Buyer-sourced	0	FAIL
AX-2025-019332	AMB-2411-X6617	Janoshik	2025-Q2	99.93	5.33	95.3	Buyer-sourced	0	FAIL
AX-2025-019333	AMB-2411-X6617	Janoshik	2025-Q2	99.90	6.37	99.6	Buyer-sourced	0	FAIL
AX-2025-019334	AMB-2411-X6617	Janoshik	2025-Q2	99.89	5.64	102.7	Laboratory-retained	0	FAIL
AX-2025-019335	AMB-2411-X6617	PeptideMeter	2025-Q2	99.68	5.68	88.6	Buyer-sourced	2	FAIL
AX-2025-019337	AMB-2411-X6617	VendorInvestigate	2025-Q2	99.93	6.12	96.9	Buyer-sourced	0	PASS
AX-2025-019338	AMB-2411-X6617	Janoshik	2025-Q2	99.93	5.29	—	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Epitalon records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042008	AMB	AMB-2602-Y6433	Janoshik	2026-Q3	99.30	8.75	105.1	Buyer-sourced	PASS
AX-2026-042009	AMB	AMB-2602-Y6433	VendorInvestigate	2026-Q3	99.16	8.62	102.3	Buyer-sourced	FAIL
AX-2026-042010	AMB	AMB-2602-Y6433	Janoshik	2026-Q3	99.09	8.20	103.4	Laboratory-retained	FAIL
AX-2026-042007	AMB	AMB-2602-Y6433	Janoshik	2026-Q3	99.42	8.62	93.8	Buyer-sourced	FAIL
AX-2026-042468	Homopeptide	HOMO-2512-A5108	Janoshik	2026-Q2	99.93	7.81	100.8	Buyer-sourced	PASS
AX-2026-042463	Homopeptide	HOMO-2512-A5108	Janoshik	2026-Q2	99.93	7.68	93.2	Buyer-sourced	FAIL
AX-2026-042041	HYB	HYB-2603-U7133	Janoshik	2026-Q2	99.65	6.82	95.3	Buyer-sourced	FAIL
AX-2026-042470	Homopeptide	HOMO-2512-A5108	Janoshik	2026-Q2	99.63	7.99	—	Buyer-sourced	FAIL

Other recent AMB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042002	Semaglutide	AMB-2607-N6274	VendorInvestigate	2026-Q3	98.23	6.37	97.1	Buyer-sourced	1	MARGINAL
AX-2026-042012	GHRP-6	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-041974	Tirzepatide	AMB-2603-C5112	Nordanalyt	2026-Q3	98.20	3.41	—	Buyer-sourced	0	PASS
AX-2026-041975	Tirzepatide	AMB-2603-C5112	Medutest	2026-Q3	97.88	3.45	106.9	Laboratory-retained	0	PASS
AX-2026-042005	Semaglutide	AMB-2607-N6274	PeptideMeter	2026-Q3	98.09	6.48	98.6	Buyer-sourced	1	MARGINAL
AX-2026-042008	Epitalon	AMB-2602-Y6433	Janoshik	2026-Q3	99.30	8.75	105.1	Buyer-sourced	0	PASS
AX-2026-042021	TB-500	AMB-2602-P5987	VendorInvestigate	2026-Q3	99.86	4.79	101.4	Buyer-sourced	0	PASS
AX-2026-042015	GHRP-6	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS